Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMycelx Di Regulatory News (MYX)

Share Price Information for Mycelx Di (MYX)

Share Price is delayed by 15 minutes
Get Live Data
64.00    2.00 (3.23%)
Bid:
63.00
Ask:
65.00
Spread: 2.00 (3.175%)
Market Cap: £15.59m
MYX Live PriceLast checked at - London Stock Exchange

Intraday Mycelx Di Share Chart

Trading Update

23 Sep 2024 07:00

RNS Number : 2035F
MyCelx Technologies Corporation
23 September 2024
 

The information contained within this Announcement is deemed by MYCELX Technologies Corporation to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014 as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018 ("MAR").

 

23 September 2024

MYCELX Technologies Corporation

("MYCELX" or the "Company")

Trading Update

MYCELX Technologies Corporation (AIM: MYX), the clean water and clean air technology company, announces a trading update following changes to the customer's project timeline at one of its REGEN installations for a customer in Nigeria.

 

As set out in the announcement dated 23 August 2024, the Company highlighted that the outturn for the current financial year would be dependent on projects meeting delivery timelines with one significant project in particular expecting to be recognised in December when factory acceptance testing was due to be completed.

 

Subsequent to successful achievement of the last project milestone three weeks ago for the above-mentioned project, the Company has just recently been made aware by the customer that the next major milestone has been delayed for several weeks. While not unusual for a project of this size and complexity, this delay comes at a critical time in terms of MYCELX's ability to deliver its equipment as scheduled. The Board recognises that there is now a strong possibility this delay will affect the Company's factory acceptance testing in mid-December, and revenue recognition in 2024, and as a result, the Board has made the prudent decision to shift anticipated revenue from the project from Q4 2024 to Q1 2025. The Company has accordingly revised its 2024 revenue forecast of $9.5 million to $4.5-$5.0 million and will recognise the project value of $5.4 million in 2025.

 

There will be no loss of revenue for the Company and minimal impact to the forecasted year end cash balance given MYCELX will continue to receive milestone payments that keep the project cash flow positive despite the delay. The Company will be announcing its Interim Results in the coming days.

 

The Company looks forward to working closely with its partners in Nigeria to successfully deliver this project and continuing its momentum in REGEN adoption in the oil and gas market.

 

Connie Mixon, CEO, commented:

 

"While this project will be marginally delayed, there will be no significant effect on the business since revenue is simply shifting from Q4 2024 to Q1 2025 and impact to the Company's cash balance at year end is minimal. We look forward to completion of this project which is our fourth installation in Nigeria where our technology is enabling producers to achieve their goals of better water treatment and a cleaner environment.

 

We plan to announce our Interim Results over the coming days, which will give the market further insight into the progress across our core markets."

 

For further information, please contact:

MYCELX Technologies Corporation

Connie Mixon, CEO

Kim Slayton, CFO

 

 

 

Tel: +1 888 306 6843

Canaccord Genuity Limited (Nominated Adviser and Sole Broker)

Henry Fitzgerald-O'Connor

Charlie Hammond

 

 

Tel: +44 20 7523 8000

Celicourt Communications (Financial PR)

Mark Antelme

Jimmy Lea

Charlie Denley-Myerson

 

 

Tel: +44 20 7770 6424

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTQKNBBPBKKNCB
Date   Source Headline
22nd Feb 20247:00 amRNSSaudi Arabia Business Operation Sale
21st Nov 20237:00 amRNSContract Update
16th Nov 20237:00 amRNSTrading Update
26th Sep 20233:10 pmRNSResult of Annual Meeting
20th Sep 20237:00 amRNSHalf Year Results Statement
11th Jul 20237:00 amRNSContract Award
5th Jul 20233:28 pmRNSHolding(s) in Company
3rd Jul 20232:37 pmRNSContract Award & PFAS Update
21st Jun 20237:00 amRNSMailing of AR and Notice of 2023 Annual Meeting
18th May 20237:00 amRNSFinal Results for the Year Ending 31 December 2022
12th May 20237:00 amRNSHolding(s) in Company
17th Apr 20237:00 amRNSSuccessful leach testing of PFAS media
14th Mar 20234:50 pmRNSClosure of Restricted Stock Line
8th Mar 20237:00 amRNSPilot Testing Agreement for PFAS Remediation
13th Feb 20237:00 amRNSOperational Update
31st Jan 20237:00 amRNSTrading Update
24th Jan 20237:00 amRNSContract Secured for PFAS Remediation System
8th Dec 20227:00 amRNSTrading Update
27th Sep 20227:00 amRNSHalf Year Results Statement
15th Sep 20227:00 amRNSTrading Update
6th Sep 20222:30 pmRNSHolding(s) in Company
30th Aug 20227:00 amRNSNew Project Awards and Operations Update
13th Jul 20223:32 pmRNSResult of Annual Meeting
13th Jun 20227:00 amRNS2021 Annual Report & Notice of 2022 Annual Meeting
17th May 20227:00 amRNSFinal Results for Year Ending 31 December 2021
3rd May 20227:00 amRNSDirector/PDMR Shareholding
3rd May 20227:00 amRNSChange of Main Office Address
23rd Mar 20229:17 amRNSTR1
21st Mar 20225:56 pmRNSBroker Option
16th Mar 20224:09 pmRNSHolding(s) in Company
11th Mar 20221:10 pmRNSDealings by Directors
11th Mar 20227:00 amRNSProposed Placing and Subscription
11th Feb 20227:00 amRNSTrading Update
2nd Feb 202211:07 amRNSHolding(s) in Company
25th Jan 20227:00 amRNSSuccessful Trial of PFAS Remediation System
10th Jan 20227:00 amRNSAward of Green Economy Mark
23rd Nov 20212:36 pmRNSHolding(s) in Company
11th Nov 202111:51 amRNSDealings by Directors
9th Nov 20214:42 pmRNSDirector/PDMR Shareholding
5th Nov 20217:00 amRNSDirector/PDMR Shareholding
28th Oct 20214:34 pmRNSHolding(s) in Company
14th Oct 20217:00 amRNSMiddle East Contract Win
29th Sep 20217:00 amRNSHalf Year Results Statement
31st Aug 20217:00 amRNSNotice of Interim Results & Investor Presentation
11th Aug 20217:00 amRNSHolding(s) in Company
4th Aug 20217:00 amRNSContract Award and Contract Extension
7th Jul 20215:41 pmRNSResult of AGM
4th Jun 20218:00 amRNSMailing of Annual Financial Report and AM Notice
26th May 20217:00 amRNSFinal Results for the year ending 31 December 2020
19th May 20217:00 amRNSInvestor Presentation

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.